Chronic obstructive pulmonary disease in China: the potential role of indacaterol (original) (raw)
Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population
Niyati Prasad
Respiratory medicine, 2012
View PDFchevron_right
Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: A 12-week, placebo-controlled study
Masakazu Ichinose
Respirology, 2012
View PDFchevron_right
Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study
Mark Higgins
BMC Pulmonary Medicine, 2010
View PDFchevron_right
Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort
Mukesh Singh
International journal of chronic obstructive pulmonary disease, 2013
View PDFchevron_right
Comparative efficacy of indacaterol in chronic obstructive pulmonary disease
Kenneth Chapman
International journal of chronic obstructive pulmonary disease, 2012
View PDFchevron_right
The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D
James Donohue
Pulmonary pharmacology & therapeutics, 2015
View PDFchevron_right
Efficacy of a new once-daily long-acting inhaled 2-agonist indacaterol versus twice-daily formoterol in COPD
Kian Chung
Thorax, 2010
View PDFchevron_right
Role of indacaterol, a once-daily bronchodilator, in chronic obstructive pulmonary disease
Samir Sultan
Journal of thoracic disease, 2013
View PDFchevron_right
Safety of indacaterol in the treatment of patients with COPD
James Donohue
International Journal of Chronic Obstructive Pulmonary Disease, 2011
View PDFchevron_right
Long-term safety and efficacy of indacaterol, a long-acting beta-agonist, in subjects with COPD: a randomized, placebo-controlled study.
Kenneth Chapman
View PDFchevron_right
Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review
Cristoforo Incorvaia
International Journal of Chronic Obstructive Pulmonary Disease, 2013
View PDFchevron_right
Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: A randomized, crossover study
AMIR IQBAL
Pulmonary Pharmacology & Therapeutics, 2011
View PDFchevron_right
Long-term Safety and Efficacy of Indacaterol, a Long-Acting b2-Agonist, in Subjects With COPD A Randomized, Placebo-Controlled Study
Kenneth Chapman
View PDFchevron_right
A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study
Chaicharn Pothirat
International Journal of Chronic Obstructive Pulmonary Disease, 2015
View PDFchevron_right
The effect of indacaterol during an acute exacerbation of COPD
P. Rogliani, M. Cazzola, Marco Sabatini
Pulmonary Pharmacology & Therapeutics, 2013
View PDFchevron_right
Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial
Chin Rhee
Trials, 2017
View PDFchevron_right
Indacaterol 75 μg: COPD patients’ perceived onset
Dove Medical Press
2014
View PDFchevron_right
Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers
Tobias Welte
European Journal of Drug Metabolism and Pharmacokinetics, 2014
View PDFchevron_right
Once-daily indacaterol 75 µg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients’ perceived onset of effect
Craig Laforce
International Journal of Chronic Obstructive Pulmonary Disease, 2014
View PDFchevron_right
Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-Fluticasone
Ashiq Choudhury
Bangabandhu Sheikh Mujib Medical University Journal, 2022
View PDFchevron_right
The role of long-acting muscarinic antagonist/long-acting β agonist fixed-dose combination treatment for chronic obstructive pulmonary disease in China: a narrative review
Aseem Srivastava
Journal of Thoracic Disease, 2021
View PDFchevron_right
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol
E. Puxeddu, Josuel Ora
Respiratory Medicine, 2013
View PDFchevron_right
Indacaterol/glycopyrronium vs tiotropium or glycopyrronium in treatment naive COPD patients: a pooled analysis
Pritam Gupta
Airway pharmacology and treatment, 2018
View PDFchevron_right
Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
N. Roskell, Alan Hamilton, Bernd Disse
International Journal of Chronic Obstructive Pulmonary Disease, 2014
View PDFchevron_right
Indacaterol/Glycopyrronium Combination for COPD
Josuel Ora
Pulmonary Therapy, 2017
View PDFchevron_right
Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: A pooled analysis
Pritam Gupta
Respirology, 2019
View PDFchevron_right
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
Jana Skoupa
The New England journal of medicine, 2016
View PDFchevron_right
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial
Dina Diaz
Respiratory research, 2017
View PDFchevron_right
Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: a four-center, open-label, randomized, controlled study
W. Zhang
BMC Complementary and Alternative Medicine, 2012
View PDFchevron_right
24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: A comparison with placebo and salmeterol
Masakazu Ichinose
Respiratory Medicine, 2010
View PDFchevron_right
The impact of 2011 and 2017 Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines on allocation and pharmacological management of patients with COPD in Taiwan: Taiwan Obstructive Lung Disease (TOLD) study
Yu-feng Wei
International Journal of Chronic Obstructive Pulmonary Disease
View PDFchevron_right
Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD
Roy Pleasants
International Journal of Chronic Obstructive Pulmonary Disease, 2015
View PDFchevron_right
Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives
Chin Rhee
Advances in Therapy
View PDFchevron_right
Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study
Kenneth Chapman
The Lancet. Respiratory medicine, 2013
View PDFchevron_right
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD
Kian Chung
Respiratory medicine, 2011
View PDFchevron_right